المعالجة الموضعية لمرضى الصداف الشائع بالموميتازون فوروات والكالسيبوتريول (دراسة مقارنة/ خبرة مشفى الأسد الجامعي باللاذقية)
Abstract
الصداف مرض التهابي مزمن معاود يصيب الجلد والفروة والمفاصل، يكون شديداً أو خفيفاً. الصداف الشائع هو أكثر أنماط الصداف مشاهدة.
تعتبر مراهم الكالسيبوتريول والموميتازون فوروات من المعالجات الموضعية الشائعة الاستخدام في الصداف الشائع، مع أن آلية تأثيرها مختلفة.
تمت مقارنة الفعالية السريرية لمشاركة الدواءين مع بعضهما ولكل منهما على انفراد.
تم توزيع المرضى الـ 120 وبشكل عشوائي على ثلاث مجموعات متساوية، عولج المرضى في كل مجموعة لمدة 4 أسابيع إما بمرهم الكالسيبوتريول أو بمرهم الموميتازون فوروات أو بمشاركة المرهمين معاً.
أدت المعالجةإلى إنقاص شدة PSAI في نهاية المعالجة بمعدل 73.62 % في مجموعة المشاركة و 46.5 % في مجموعة الكالسيبوتريول و 57.5% في مجموعة الموميتازون. وكان معدل التراجع بعد أسبوعين 52.53 % 34 % و 42.6 % على التوالي.
أظهرت المعالجة المشاركة بأنها أكثر فعالية وأقل تأثيرات جانبية من المعالجة المفردة بأي من الدواءين.
Background: Psoriasis is a chronic and recurrant inflammatory disease that affects the skin, scalp, and joints. It ranges in severity from mild to severe. Psoriasis vulgaris is the most common typ of disease.
Calcipotriol and mometasone furoate are common topical treatments used for psoriasis vulgaris, with different mode of action.
Objective: We compared the clinical efficacy of the combination of the two agents with each other alone.
Methods: 120 patient were randomly placed in three groups and treated topicaly along
4-weeks with either calcipotriol ointment 50 µg/g, mometasone furoate ointment 0,1 %, or a combination of the two agents together.
Results: The mean percentage reduction in PASI from baseline to end of treatment was 73,62% in the combination group, 46,5% in calcipotriol group, and 57,5% in mometasone group. The reduction after two weeks was 52,53%, 34%, and 42,6% respectively.
Conclusion: The combination therapy shows superior efficacy and less side effects compared with the singel therapy.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The authors retain the copyright and grant the right to publish in the magazine for the first time with the transfer of the commercial right to Tishreen University Journal for Research and Scientific Studies - Health Sciences Series
Under a CC BY- NC-SA 04 license that allows others to share the work with of the work's authorship and initial publication in this journal. Authors can use a copy of their articles in their scientific activity, and on their scientific websites, provided that the place of publication is indicted in Tishreen University Journal for Research and Scientific Studies - Health Sciences Series . The Readers have the right to send, print and subscribe to the initial version of the article, and the title of Tishreen University Journal for Research and Scientific Studies - Health Sciences Series Publisher
journal uses a CC BY-NC-SA license which mean
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material
- The licensor cannot revoke these freedoms as long as you follow the license terms.
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- NonCommercial — You may not use the material for commercial purposes.
- ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.